Tumor Immunotherapy Using A2A Adenosine Receptor Antagonists

The A2A adenosine receptor (A2AAR) plays critical roles in human physiology and pathophysiology, which makes it an important drug target. Previous drug-discovery efforts targeting the A2AAR have been focused on the use of A<sub&...

Full description

Bibliographic Details
Main Authors:	Jinfeng Zhang, Wenzhong Yan, Wenwen Duan, Kurt Wüthrich, Jianjun Cheng
Format:	Article
Language:	English
Published:	MDPI AG 2020-09-01
Series:	Pharmaceuticals
Subjects:	GPCR immuno-oncology Parkinson’s disease drug binding modes cancer therapy
Online Access:	https://www.mdpi.com/1424-8247/13/9/237

id	doaj-14504f5166644762b43ed8fa583b9d56
record_format	Article
spelling	doaj-14504f5166644762b43ed8fa583b9d562020-11-25T03:00:09ZengMDPI AGPharmaceuticals1424-82472020-09-011323723710.3390/ph13090237Tumor Immunotherapy Using A<sub>2A</sub> Adenosine Receptor AntagonistsJinfeng Zhang0Wenzhong Yan1Wenwen Duan2Kurt Wüthrich3Jianjun Cheng4iHuman Institute, ShanghaiTech University, Shanghai 201210, ChinaiHuman Institute, ShanghaiTech University, Shanghai 201210, ChinaiHuman Institute, ShanghaiTech University, Shanghai 201210, ChinaiHuman Institute, ShanghaiTech University, Shanghai 201210, ChinaiHuman Institute, ShanghaiTech University, Shanghai 201210, ChinaThe A<sub>2A</sub> adenosine receptor (A<sub>2A</sub>AR) plays critical roles in human physiology and pathophysiology, which makes it an important drug target. Previous drug-discovery efforts targeting the A<sub>2A</sub>AR have been focused on the use of A<sub>2A</sub>AR antagonists for the treatment of Parkinson’s disease. More recently, the A<sub>2A</sub>AR has attracted additional attention for its roles in immuno-oncology, and a number of A<sub>2A</sub>AR antagonists are currently used as lead compounds for antitumor drugs in both preclinical models and clinical trials. This review surveys recent advances in the development of A<sub>2A</sub>AR antagonists for cancer immunotherapy. The therapeutic potential of representative A<sub>2A</sub>AR antagonists is discussed based on both animal efficacy studies and clinical data.https://www.mdpi.com/1424-8247/13/9/237GPCRimmuno-oncologyParkinson’s diseasedrug binding modescancer therapy
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Jinfeng Zhang Wenzhong Yan Wenwen Duan Kurt Wüthrich Jianjun Cheng
spellingShingle	Jinfeng Zhang Wenzhong Yan Wenwen Duan Kurt Wüthrich Jianjun Cheng Tumor Immunotherapy Using A<sub>2A</sub> Adenosine Receptor Antagonists Pharmaceuticals GPCR immuno-oncology Parkinson’s disease drug binding modes cancer therapy
author_facet	Jinfeng Zhang Wenzhong Yan Wenwen Duan Kurt Wüthrich Jianjun Cheng
author_sort	Jinfeng Zhang
title	Tumor Immunotherapy Using A<sub>2A</sub> Adenosine Receptor Antagonists
title_short	Tumor Immunotherapy Using A<sub>2A</sub> Adenosine Receptor Antagonists
title_full	Tumor Immunotherapy Using A<sub>2A</sub> Adenosine Receptor Antagonists
title_fullStr	Tumor Immunotherapy Using A<sub>2A</sub> Adenosine Receptor Antagonists
title_full_unstemmed	Tumor Immunotherapy Using A<sub>2A</sub> Adenosine Receptor Antagonists
title_sort	tumor immunotherapy using a<sub>2a</sub> adenosine receptor antagonists
publisher	MDPI AG
series	Pharmaceuticals
issn	1424-8247
publishDate	2020-09-01
description	The A<sub>2A</sub> adenosine receptor (A<sub>2A</sub>AR) plays critical roles in human physiology and pathophysiology, which makes it an important drug target. Previous drug-discovery efforts targeting the A<sub>2A</sub>AR have been focused on the use of A<sub>2A</sub>AR antagonists for the treatment of Parkinson’s disease. More recently, the A<sub>2A</sub>AR has attracted additional attention for its roles in immuno-oncology, and a number of A<sub>2A</sub>AR antagonists are currently used as lead compounds for antitumor drugs in both preclinical models and clinical trials. This review surveys recent advances in the development of A<sub>2A</sub>AR antagonists for cancer immunotherapy. The therapeutic potential of representative A<sub>2A</sub>AR antagonists is discussed based on both animal efficacy studies and clinical data.
topic	GPCR immuno-oncology Parkinson’s disease drug binding modes cancer therapy
url	https://www.mdpi.com/1424-8247/13/9/237
work_keys_str_mv	AT jinfengzhang tumorimmunotherapyusingasub2asubadenosinereceptorantagonists AT wenzhongyan tumorimmunotherapyusingasub2asubadenosinereceptorantagonists AT wenwenduan tumorimmunotherapyusingasub2asubadenosinereceptorantagonists AT kurtwuthrich tumorimmunotherapyusingasub2asubadenosinereceptorantagonists AT jianjuncheng tumorimmunotherapyusingasub2asubadenosinereceptorantagonists
_version_	1724699040776454144

Tumor Immunotherapy Using A<sub>2A</sub> Adenosine Receptor Antagonists

Similar Items